Please login to the form below

Not currently logged in


This page shows the latest neurology news and features for those working in and with pharma, biotech and healthcare.

Novartis files for approval of MS drug in EU, US

Novartis files for approval of MS drug in EU, US

In the EXPAND study presented at this year’s American Academy of Neurology (AAN) conference, siponimod showed a 14-20% reduced risk of disability progression in SPMS compared to placebo at

Latest news

More from news
Approximately 8 fully matching, plus 146 partially matching documents found.

Latest Intelligence

  • Tackling a formidable foe Tackling a formidable foe

    Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck. ... Ali-Frederic Ben-Amor, Vice President, Global Medical Affairs for Neurology &Immunology, Merck, epitomises the field’s passion and refusal to take a

  • A quest for innovative solutions A quest for innovative solutions

    Ecosystem. “I have the most beautiful job in the company because my team and I are exposed to the change externally, ”says Erik Janssen, UCB’s head of innovative solutions, Neurology

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen was the largest seller in the CNS market in 2017 and this is forecast to continue, ”says Rahael Maladwala, analyst, neurology and ophthalmology, GlobalData. ... Neurology experienced slow growth, largely because few diseases are very well

  • Deal Watch October 2016 Deal Watch October 2016

    $330m. Neurology 2016. Aspen. 5 anesthetics. $770m royalties. $592m. 1.3. Neurology 2014. ... Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

  • Deal Watch August 2016 Deal Watch August 2016

    So the product, which is an orphan drug, ended up in the portfolio of a $10bn company focussed on GI, dermatology and neurology and which was under investigation by the SEC

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

  • PRMA Consulting Ltd

    Our experience encompasses a wide range of indications, including; cardiovascular and renal, gastroenterology, immunology, infectious diseases and vaccines, metabolism and endocrinology, neurology and psychiatry, oncology/hematology, ophthalmology,

  • Bringing the NHS into the 21st century

    We have consultants specialising in cardiology, endocrine, ENT, gynaecology, haematology, neurology, respiratory, orthopaedics, rheumatology, and urology.

  • Forecasting in Forgotten Markets

    Forecasting in Forgotten Markets. In this article, Anthony Woodhead, Business Development Manager for Black Swan Analysis, discusses the challenges facing innovators in markets like Dementia, which has attracted significant investment over time but

  • Lighthouse Medical Communications US bolster their senior scientific team

    number of key therapeutic areas such endocrinology, neurology, oncology, hematology, women’ s health and rare diseases.

  • 90TEN boosts PR division with hires from Biosector 2 and Tonic

    Patel moves to 90TEN following three years at Tonic Life Communications, where she worked on international accounts spanning oncology, neurology and medical devices.

More from PMHub
Approximately 1 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...